This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-05 and is reviewed periodically as new material appears.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
== Products and services == Therapeutic antibody discovery Cell-receptor monoclonal antibody development In vivo animal study-grade antibodies development Molecular modeling Antibody sequencing Anti-idiotype antibody production Anti-protein antibodies for pharmacokinetics studies Immunogenicity assays for reagents and controls Immunoassay development Ligand-binding assay analysis Drug potency assay analysis Cell bank storage Full technical and project management
The integumentary system (skin) is made up of three layers: the outermost epidermis, the dermis and the hypodermis. The epidermis is typically 10 to 30 cells thick; its main function is to provide a waterproof layer. Its outermost cells are constantly lost; its bottommost cells are constantly dividing and pushing upward. The middle layer, the dermis, is 15 to 40 times thicker than the epidermis. The dermis is made up of many components, such as bony structures and blood vessels. The hypodermis is made up of adipose tissue, which stores lipids and provides cushioning and insulation. The thickness of this layer varies widely from species to species; marine mammals require a thick hypodermis (blubber) for insulation, and right whales have the thickest blubber at 20 inches (51 cm). Although other animals have features such as whiskers, feathers, setae, or cilia that superficially resemble it, no animals other than mammals have hair. It is a definitive characteristic of the class, though some mammals have very little.
To allow bone mineralization to take place, osteoblasts secrete tissue-nonspecific alkaline phosphatase into the osteoid to break down pyrophosphate, an extracellular inhibitor of hydroxyapatite precipitation which otherwise prevents precipitation of hydroxyapetite crystals from extracellular fluid which is supersaturated in Ca2+ and PO3−4 ions.
== Pathology == Mutations in the PLOD1 gene have been linked to kyphoscoliotic Ehlers–Danlos syndrome (kEDS, in the past EDS VI).Mutations in the PLOD2 gene have been linked to Bruck syndrome in humans. A deficiency in its cofactor vitamin C is associated with scurvy.
In such a situation the risk for another affected child is higher than in a genotypically normal parent. Type III collagen could also be important in several other human diseases. Increased amounts of type III collagen are found in many fibrotic conditions such as liver and kidney fibrosis, and systemic sclerosis. This has led to a search for serum biomarkers that could be used for diagnosing these conditions without having to obtain a tissue biopsy. The most widely used biomarker is the N-terminal propeptide of type III procollagen, which is cleaved off during the biosynthesis of type III collagen.
Sources: en.wikipedia.org
== Alternative names == Type V collagen has a few alternative names alpha 1 These include: type V collagen preproprotein, CO5A1_HUMAN, and collagen type V alpha. Type V collagen can also be abbreviated to COLV or collagen V.
Samarium-151 (151Sm) has a half-life of 94.6 years, undergoing low-energy beta decay, and has a fission product yield of 0.4203% for thermal neutrons and 235U, about 39% of 149Sm's yield. The yield is somewhat higher for 239Pu. Its neutron absorption cross section for thermal neutrons is high at 15200 barns, about 38% of 149Sm's absorption cross section, or about 20 times that of 235U. Since the ratios between the production and absorption rates of 151Sm and 149Sm are almost equal, the two isotopes should reach similar equilibrium concentrations. Since 149Sm reaches equilibrium in about 500 hours (20 days), 151Sm should reach equilibrium in about 50 days. As this is still much shorter than its radioactive half-life, decay will hardly affect this equilibrium while in the reactor. Since nuclear fuel is used for several years (burnup) in a nuclear power plant, the final amount of 151Sm in the spent nuclear fuel at discharge is only a small fraction of the total 151Sm produced during the use of the fuel. According to one study, the mass fraction of 151Sm in spent fuel is about 0.0025 for heavy loading of MOX fuel and about half that for uranium fuel, which is roughly two orders of magnitude less than the mass fraction of about 0.15 for the medium-lived fission product 137Cs. The decay energy of 151Sm is also about an order of magnitude less than that of 137Cs. The low yield, low survival rate, and low decay energy mean that 151Sm has insignificant nuclear waste impact compared to the two main medium-lived fission products 137Cs and 90Sr.
Individuals receiving psychiatric treatment are commonly referred to as patients but may also be called clients, consumers, or service recipients. They may come under the care of a psychiatric physician or other psychiatric practitioners by various paths, the two most common being self-referral or referral by a primary care physician. Alternatively, a person may be referred by hospital medical staff, by court order, involuntary commitment, or, in countries such as the UK and Australia, by sectioning under a mental health law. A psychiatrist or medical provider evaluates people through a psychiatric assessment for their mental and physical condition. This usually involves interviewing the person and often obtaining information from other sources such as other health and social care professionals, relatives, associates, law enforcement personnel, emergency medical personnel, and psychiatric rating scales. A mental status examination is carried out, and a physical examination is usually performed to establish or exclude other illnesses that may be contributing to the alleged psychiatric problems. A physical examination may also serve to identify any signs of self-harm; this examination is often performed by someone other than the psychiatrist, especially if blood tests and medical imaging are performed. Like most medications, psychiatric medications can cause adverse effects in patients, and some require ongoing therapeutic drug monitoring, for instance full blood counts, serum drug levels, renal function, liver function or thyroid function.
=== U.S. license to sell Venezuelan oil to Cuba === On 25 February, the United States emitted a license allowing companies to resell Venezuelan oil to Cuba's private sector. The U.S. Treasury Department indicated that the exchange must "support the Cuban people, including the private sector".
The first commercial oil well in Canada became operational in 1858 at Oil Springs, Ontario. Businessman James Miller Williams dug several wells between 1855 and 1858 before discovering a rich reserve of oil four metres below ground. Williams extracted 1.5 million litres of crude oil by 1860, refining much of it into kerosene lamp oil. Williams's well became commercially viable a year before Drake's Pennsylvania operation and could be argued to be the first commercial oil well in North America. The discovery at Oil Springs touched off an oil boom which brought hundreds of speculators and workers to the area. Advances in drilling continued into 1862 when local driller Shaw reached a depth of 62 metres using the spring-pole drilling method. On January 16, 1862, after an explosion of natural gas, Canada's first oil gusher came into production, shooting into the air at a recorded rate of 480 cubic metres (3,000 bbl) per day. By the end of the 19th century the Russian Empire, particularly the Branobel company in Azerbaijan, had taken the lead in production.
Sources: en.wikipedia.org
==== Member of the Order of the British Empire (MBE) ==== Civil Division Kopu Brown. For public services, lately as Secretary of the Ministry of Internal Affairs. Naomi Iro. For services to the community.
Spironolactone is closely related structurally to other clinically used spirolactones such as canrenone, potassium canrenoate, drospirenone, and eplerenone, as well as to the never-marketed spirolactones SC-5233 (6,7-dihydrocanrenone; 7α-desthioacetylspironolactone), SC-8109 (19-nor-6,7-dihydrocanrenone), spiroxasone, prorenone (SC-23133), mexrenone (SC-25152, ZK-32055), dicirenone (SC-26304), spirorenone (ZK-35973), and mespirenone (ZK-94679).
is used to control the proportion of amino acids that are unchanged. By using only alignments of proteins that had at least 85% similarity, it could be reasonably assumed that the mutations observed were direct, without any intermediate states. This means that scaling down these counts by a common factor would provide an accurate estimate of the mutation counts had the similarity been closer to 100%. It also means that the number of mutations per 100 amino acids, the
Engines (includes all models from 1998 to 2003) 1.3 L B3-ME SOHC I4 1.5 L ZL-DE DOHC I4 1.5 L ZL-VE S-VT I4 1.6 L ZM-DE DOHC I4 1.8 L FP-DE DOHC I4 2.0 L FS, 130 hp (97 kW; 132 PS) / 135 lb⋅ft (183 N⋅m) 2.0 L FS-ZE (2001 Sport 20) 2.0 L RF Diesel
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.